About: UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2007 (uk) article scientifique publié en 2007 (fr) im Juni 2007 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58408313-8050E04E-ADEA-4546-835B-4AB76D280AB7
publication date	2007-05-17 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58408313-5AEAD2C9-F7A8-491F-900C-DB0CC2F7B734
language of work or name	English
author name string	wds:Q58408313-19F0E36B-1B93-4009-93F5-A6DCF29079B2 wds:Q58408313-24FCFDD9-FAC9-4E40-9A48-4AE5FF8896DB wds:Q58408313-29E19D3B-57C0-40C9-8845-C1336BF75E2E wds:Q58408313-34377657-3C61-4E51-B568-3360335B3C4C wds:Q58408313-8B6BFE0B-5892-4342-9E9B-5D9C97DB510F wds:Q58408313-B9B72598-090A-456A-B5A6-227272E5C766 wds:Q58408313-C6E4761D-076A-42F2-8200-5E5BFBE5F26B wds:Q58408313-E36F88CE-125D-43E9-B026-DF177F26BE77
author name string	Janick Selves Sylvain Kirzin Jean-François Côté Marie-Danièle Diebold Andrew Kramar Isabelle Soubeyran Jean-François Mosnier Anne-Sophie Thirouard
rdfs:label	UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (en) UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (nl)
skos:prefLabel	UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (en) UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (nl)
name	UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (en) UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan (nl)
author	wds:Q58408313-73D9C9FD-4F26-45F6-BB77-AF3A82ADE687 wds:Q58408313-D81B3AD7-46CE-45A5-AD2D-17BDBF860832
author	Pierre Laurent-Puig Marc Ychou
title	wds:Q58408313-5369EC7E-E0BB-4341-8BDB-811331ADE68E
title	UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan (en)
page(s)	wds:Q58408313-1EEC3775-CACC-4359-9AB6-1F5ACE4BB290
page(s)	3269-3275
instance of	wds:Q58408313-3E58EE6A-60D2-43C3-816D-DDAEE289622A
instance of	scholarly article
main subject	wds:Q58408313-24C25BFB-7AA1-44BD-83DE-A9E98401099F wds:Q58408313-7BA30B7E-A5DD-4FD1-BE6B-F0E48277FB7F wds:Q58408313-7D53404A-D2E4-4DBE-B26B-C113B580CF9D
main subject	irinotecan toxicity Patients
PubMed ID	wds:Q58408313-C0B475A1-E9EE-436D-A932-D63EC9330146
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17510208
PubMed ID	17510208
published in	wds:Q58408313-B74804CC-D2D1-4323-85B2-4ADAEC43FB40
published in	Clinical Cancer Research
issue	wds:Q58408313-21227DFC-16E1-4FC2-B7E5-1B87B96ACC70
volume	wds:Q58408313-15C0EFC1-1C8C-402B-8322-3DCB7E0B5915
issue	11
volume	13
DOI	wds:Q58408313-A7F45825-6760-4025-A6C5-3CD98B1AB546
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-06-2290
DOI	10.1158/1078-0432.CCR-06-2290
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58408313
is cites work of	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review Review of biomarkers in colorectal cancer The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Association between UGT1A128 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians Pharmacogenetics in colorectal cancer: a systematic review Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics Association of UGT1A128 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years An overview of the recent progress in irinotecan pharmacogenetics Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer UGT1A128 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples Africa: continent of genome contrasts with implications for biomedical research and health Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question Review of systemic therapies for locally advanced and metastatic rectal cancer Pharmacogenomics of chemotherapeutic susceptibility and toxicity OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy Clinical implications of UGT1A128 genotype testing in colorectal cancer patients UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer Approaches to biomarkers in human colorectal cancer: looking back, to go forward Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software